Skip to main content
NewslettersWatchlist

Dexcom Inc(DXCM-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low129.74
Day High132.36
Open:131.26
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.
Select a category then submit the form to load news
Motley Fool
2 Growth Stocks to Buy Hand Over Fist in April
Motley Fool
Market Cap Game Show: Andy Cross vs. Bill Mann
Barchart
Stocks End Lower as Hawkish Fed Comments Push Bond Yields Higher
Motley Fool
2 Medical Device Stocks to Buy Hand Over Fist in March
Barchart
Stocks Climb Before the Open as Investors Await U.S. Economic Data and Powell’s Testimony, ECB Decision in Focus
Barchart
Stocks Settle Higher and Bond Yields Fall on Fed Rate Cut Optimism
Barchart
Stocks Post Moderate Gains as Fed Chair Powell Signals Rate Cuts This Year
Motley Fool
Adding $1,000 to These Top Growth Stocks Would Be a Brilliant Move
Motley Fool
Got $1,000? Buy These Hot Growth Stocks Before They Take Off
Motley Fool
These 2 Growth Stocks Could Soar 33% and 45% According to Wall Street Analysts. Are They Smart Buys Now?
Motley Fool
Wall Street's Next Stock-Split Stocks Are Liable to Be Familiar Names
Motley Fool
2 No-Brainer Healthcare Stocks to Buy Right Now
Barchart
S&P 500 and Nasdaq 100 Set Record Highs on Economic Optimism
Barchart
Stocks Gain on Fed-Friendly Inflation Report
Motley Fool
DexCom (DXCM) Q4 2023 Earnings Call Transcript
Motley Fool
Prediction: 2 Stocks That Could Trounce the Market
Motley Fool
2 Phenomenal Stocks to Buy for the New Year
Motley Fool
These 2 Growth Stocks Are Brilliant Buys for the New Year
Motley Fool
2 Growth Stocks That Could Make You Richer in 2024 and Beyond
Motley Fool
History Says the Nasdaq Will Soar in 2024: 1 Stock-Split AI Growth Stock to Buy Now and Hold Forever
Motley Fool
1 Stock-Split Stock to Buy Hand Over Fist in 2024 and 1 to Avoid
Motley Fool
These 3 Companies Can Be the Next Stock-Split Stocks in 2024
Motley Fool
Meet the Stock-Split Stock Warren Buffett Is Likeliest to Buy in 2024
Motley Fool
3 Stock-Split Stocks Billionaires Are Piling Into Ahead of 2024
The Globe and Mail
Innovation ETFs promise high-growth potential, but beware volatility
Motley Fool
3 Stock-Split Stocks With 51% to 128% Upside in 2024, According to Select Wall Street Analysts
Motley Fool
Pet Parents Keep Spending
Motley Fool
1 Stock-Split Stock to Buy Hand Over Fist in December, and 1 to Avoid Like the Plague
Motley Fool
Investing $5,000 in These 3 Stocks Could Make You Rich
Motley Fool
3 Growth Stocks to Buy With $1,000 Right Now
Motley Fool
Ozempic Might Be Helping Abbott Laboratories and DexCom Stock. Here's How.
Motley Fool
3 Stock-Split Stocks Billionaires Are Buying Hand Over Fist

Profile

DexCom, Inc. is a medical device company focused on the design, development and commercialization of continuous glucose monitoring systems (CGM). These are for ambulatory use by people with diabetes and by healthcare providers for the treatment of diabetic and non-diabetic patients. A key element of DexCom's monitoring system technology is the continuous measure of patient's blood glucose level and transmission of that information to a small cell phone-sized receiver in real time. The company's monitoring systems aim to provide real-time continuous blood glucose values, trend data and alerts to assist patients in managing their blood glucose levels.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2024.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2024 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.